PDCD1 and non-small cell lung carcinoma: To the best of our knowledge, this study is the first and most comprehensive systematic review and meta-analysis which summarizes and evaluates the correlation between irAE occurrence and clinical outcomes after receiving anti-PD-1 antibodies in NSCLC.